A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs CLR 1404 I-131 (Primary)
- Indications Brain cancer; Hodgkin's disease; Lymphoma; Neuroblastoma; Sarcoma
- Focus Adverse reactions
- Sponsors Cellectar Biosciences
- 26 Mar 2018 Status changed from planning to not yet recruiting.
- 19 Mar 2018 According to a Cellectar Biosciences media release, company expects to initiate this study during the second quarter of 2018.
- 22 Jan 2018 According to a Cellectar Biosciences media release, this trial is expected to initiate in 2018.